Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine delivery
Following months of collaborative development work, Aerogen ® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006016/en/
Aerogen Solo vibrating mesh nebulizer (Photo: Business Wire)
The aerosolised vaccine is directly inhaled via a cup dispenser into the patient’s airway. This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia™ has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.1
Inoculation by the inhaled aerosol route requires a considerably smaller volume of vaccine to be used and therefore provides the capacity to allow a much larger number of patients to cost-effectively access the CanSinoBIO vaccine than would have been possible using an injectable approach.2
John Power, Aerogen CEO & Founder said “The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination. The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”
Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO commented; “Our partnership with Aerogen started in 2013 and for almost a decade, we’ve been advancing the possibility of aerosol drug delivery. The innovative development on the inhaled delivery of COVID-19 vaccine is the testimony of our collaborative efforts. It is demonstrated that the aerosolised vaccine can stimulate mucosal immunity and significantly reduce the risk of transmission, which could be a solution to rapidly build mass immune protection and accelerate the end of the pandemic.”
CanSinoBio is preparing an application for commercial authorisation in China. Further clinical trials are in the process of being prepared for other countries.
Commercial terms of the partnership have not been disclosed.
Additional information:
About CanSinoBIO:
Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production, and commercialization of innovative vaccines for China and global public health security. It possesses five integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination, formulation, and mRNA. As of today, it has established a robust pipeline of 17 vaccines preventing 12 diseases, including the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) conditionally approved in 2021 and the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) approved in the same year.
About Aerogen:
Aerogen is the world leader in acute care aerosol drug delivery. The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology3 that mitigates the transmission of patient-generated infectious aerosol during ventilation4-9. As the only globally available closed-circuit system, Aerogen technology has been used to treat over 14 million patients in 75 countries worldwide, playing a critical role in emergency departments and intensive care units10.
References
- NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO’s COVID-19 Vaccine ConvideciaTM. http://www.cansinotech.com/html/1/179/180/651.html
- Heida R, Hinrichs WL, Frijlink HW. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19 [published online ahead of print, 2021 Aug 25]. Expert Rev Vaccines. 2021;1-18
- Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Revision U.
- Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir. Med. 2020; 167. doi:10.1016/j.rmed.2020.105987.
- Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID19 patients: A single center experience. J. Crit. Care. 2020; 58: 56–57.
- Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C et al. Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020. doi:10.1089/jamp.2020.1615.
- Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. Am J Respir Crit Care Med 2020. doi:10.1164/rccm.202009-3533SO.
- O’Toole C, McGrath JA, Joyce M, Bennett G, Byrne MA, MacLoughlin R. Fugitive Aerosol Therapy Emissions during Mechanical Ventilation: In Vitro Assessment of the Effect of Tidal Volume and Use of Protective Filters. Aerosol Air Qual Res 2020; 20. doi:10.4209/aaqr.2020.04.0176.
- Joyce M, McGrath JA, Mac Giolla Eain M, O’Sullivan A, Byrne M, MacLoughlin R. Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation. Pharmaceutics 2021; 13: 199.
- Aerogen internal data on File.
PM1087
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006016/en/
Contact information
For further information on Aerogen please contact:
Ciara Power
Global Corporate Communications Manager Aerogen,
cpower@aerogen.com
For further information on CanSino please contact:
Junhong Jing, CanSinoBIO
junhong.jing@cansinotech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Unity Game Developers Can Now Enable Direct-to-Consumer Monetization With Xsolla’s New SDK12.8.2025 16:00:00 EEST | Press release
Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announces the launch of an SDK for Unity that expands monetization capabilities for developers using the Unity engine. This new SDK is a part of Xsolla’s continued mission to unlock direct-to-consumer revenue opportunities across all platforms - mobile, PC, and the web - without complex backend work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812923531/en/ (Graphic: Xsolla) Whether building a mobile-first title, a PC game, or a browser-based game, Unity developers can now integrate payments, enable in-game purchases, and create custom storefronts without relying on closed platforms. With a fast time-to-market, developers can start selling directly to their players and retain more of their revenue from day one, while maintaining full ownership of the checkout experience, player data, and monetization strategy. Key benefit
Gogo Galileo HDX Connectivity Option Now Available on Cessna Citation CJ4 Gen312.8.2025 16:00:00 EEST | Press release
Customers who will be taking delivery of the Cessna Citation CJ4 Gen3 business jet now have the option to include the Gogo Galileo HDX connectivity solution installed on their aircraft. By integrating Gogo Galileo HDX, customers can benefit from an additional global connectivity solution that delivers exceptional performance. Announced in October 2024, the CJ4 Gen3 is expected to enter into service in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812553974/en/ Gogo Galileo HDX connectivity option now available on Cessna Citation CJ4 Gen3 (Photo Credit: Textron Aviation). The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “Cessna Citation business jets are known for their luxury and productivity,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Whether for work or entertainment, this robust solution ensures customers’ in-flight exp
Pacific Avenue Capital Partners, a Leading Middle Market Private Equity Firm, Announces the Closing of More Than $1.65 Billion in Committed Capital12.8.2025 15:30:00 EEST | Press release
Pacific Avenue Capital Partners (“Pacific Avenue”), a leading global private equity firm focused on corporate carve-outs and other complex situations in the middle market, today announced the closing of its second fund, Pacific Avenue Fund II, with more than $1.65 billion in committed capital. This includes a €100+ million sidecar vehicle that will be used alongside Fund II to pursue European opportunities. Fund II and the European sidecar were each raised in a single closing and completed in less than four months. The vehicles were significantly oversubscribed and received strong support from both new and existing investors. “We are incredibly grateful for the strong support and confidence shown by our existing and new investors,” said Chris Sznewajs, Founder and Managing Partner of Pacific Avenue. “The overwhelmingly strong demand for Fund II and the European sidecar is a clear validation of our strategy.” Pacific Avenue strives to be the premier global partner for corporate carve-ou
LevelBlue and Akamai Partner to Launch New Managed Web Application and API Protection Services12.8.2025 15:00:00 EEST | Press release
LevelBlue, a leading provider of managed security services, strategic consulting, and threat intelligence, today announced the launch of its Managed Web Application and API Protection (WAAP) security service, designed to deliver adaptive, always-on protection that can reduce risk and operational overhead for web application and API security. Powered by Akamai’s industry-leading App & API Protector technology, LevelBlue Managed WAAP combines next-gen web application firewall (WAF), distributed-denial-of service (DDoS) mitigation, bot protection, and foundational API security capabilities paired with LevelBlue’s dedicated WAAP Operations team. Organizations globally are rapidly scaling their use of applications and APIs to power digital-first strategies. According to Enterprise Strategy Group, the average number of web applications per organization is expected to grow from 145 to more than 200 within two years. Simultaneously, the number of organizations with more than half of their appl
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint ® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study12.8.2025 15:00:00 EEST | Press release
Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating the predictive utility of the MammaPrint 70-gene assay for chemotherapy benefit in patients with hormone receptor-positive, HER2-negative (HR+HER2-) early-stage breast cancer. The peer-reviewed article, titled "MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data," highlights how the MammaPrint Index predicts benefit from chemotherapy using a real-world, prospective, observational dataset. The findings are based on data from the ongoing FLEX Study (NCT03053193), a real-world data (RWD) study designed to collect whole transcriptome genomic data annotated with clinical data and outcomes from patients undergoing standard of care MammaPrint testing. This analysis included a propensity-score matched cohort of 1,002 patients with HR+HER2- breast cancer who received either chemotherapy wit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom